Piper Sandler analyst David Amsellem reiterated a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $4.29.
According to TipRanks, Amsellem is an analyst with an average return of -2.1% and a 42.17% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Supernus Pharmaceuticals, and Ironwood Pharma.
Revance Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $14.10, implying a 228.67% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $12.00 price target.
Based on Revance Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $69.8 million and a GAAP net loss of $55.7 million. In comparison, last year the company earned a revenue of $49.92 million and had a GAAP net loss of $145.95 million
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RVNC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics (RVNC) Company Description:
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
